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Abstract
Background: Previous studies regarding the lipid-cognition relation in older adults are limited and have generated
mixed results. We thus examined whether higher blood cholesterol concentrations were associated with faster
cognitive decline in a community-based longitudinal study of Chinese elderly.
Methods: The study included 1,159 Chinese adults aged over 60 years (women: 48.7%, mean age: 79.4 years), who
were free of dementia, Parkinson disease and stroke at the baseline. Blood concentrations of total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), were
assessed at the baseline. Global cognitive functions were assessed using the Chinese Mini-Mental State Examination
(MMSE) at in 2009, 2012 and 2014. Association between blood cholesterol and repeated cognitive function was
analyzed with linear mixed models, adjusting for sociodemographic information, behavior and lifestyle, depression
symptoms, physical examination, hypertension, and laboratory indexes.
Results: Higher baseline TC and LDL-C concentrations were significantly associated with greater cognitive decline.
Adjusted mean difference in cognitive decline rate, comparing two extreme quartiles, was 0.28 points (MMSE score)
per year (95% confident interval (CI): -0.54,–0.02; P-trend = 0.005) for TC and 0.42 points per year (95% CI: -0.69, -0.16;
P-trend = 0.006) for LDL-C. In a subgroup analysis, the associations between all lipids and cognitive decline appeared
to be more pronounced among individuals aged 100 years or older (n = 90), relative to others.
Conclusions: Higher blood concentrations of TC and LDL-C in late-life were associated with faster global cognitive
decline.
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Background
Cognitive impairment is one of the greatest causes of
disability and becomes the primary public health issues
globally. There are approximately 20–30% of Americans
and 8% Chinese aged over 65 years with cognitive im-
pairment, ranging from mild deficits to dementia [1–3].
Because of rapid world population ageing, the number
of people living with cognitive impairment is expected
to jump up dramatically. Currently, there have been no
reversible treatments for cognitive impairment. Early
intervention thus is significant for the prevention of
cognitive impairment.
Previous studies indicated that high non-high density
lipoprotein cholesterol (HDL-C) concentration in middle
age was a potential risk factor for subsequent occurrence
of cognitive impairment in later life [4–6]. However, the
literature did not yield consistent results when it came
to older adults [7–11]. In fact, the central nervous
system has a separate supply and circulatory system of
lipoproteins, with cholesterol solely through de novo
synthesis and at a minimum from the periphery transfer
[12]. On the one hand, high cholesterol is involved in
synaptogenesis in the brain, facilitating compensatory
repair of injured neuronal pathways in cognitive impair-
ment [13, 14]. On the other hand, high cholesterol also
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plays a role in the accumulation of amyloid beta pep-
tides, which accelerates the development of cognitive
impairment [12]. However, those contradictory results in
older adults may also lie in confounding factors when
blood lipids and cognitive function were assessed. For
example, individuals with high lipid concentrations were
more likely to use of statins, which were suggested to be
neuroprotective against cognitive dysfunction [15–18].
Previous studies were dominantly based on US or other
high-income countries. According to the report from US
Centers for Disease Control and Prevention, cholesterol-
lowering medication (primarily statins) use increased
with age, up to 48% of adults aged 75 and over [19].
Based on the new guidelines released by the American
College of Cardiology (ACC) and the American Heart
Association (AHA), a third of adults in the U.S. have
been recommended to use statins, without lipid-
cognition relation taken into account [20]. In this con-
text it is of significance to understand the association
between lipid profiles and cognitive function. Because
only 0.4% of Chinese adults living in rural areas in China
used statins, as suggested by a national survey between
2005 and 2009 [21, 22], Chinese rural areas would be
an excellent setting for studying this important re-
search question. In addition, although the risk of cog-
nitive impairment increases with age, there has been
only few studies concerning the oldest-old and there
still have been no longitudinal data of a Chinese old-
est old population.
In the current study, we examined whether higher
blood cholesterol concentrations were associated with
faster cognitive decline in a community-based longitu-
dinal study of Chinese elderly living in rural areas.
Methods
Study population
This longitudinal study based on participants aged over
60 years in the Chinese Longitudinal Healthy Longevity
Survey (CLHLS), an ongoing community-based study in
seven longevity areas in China. CLHLS was established
in half of the counties and cities in 22 of China’s 31
provinces in 1998, and then was conducted in years of
2000, 2002, 2005, 2009, 2012 and 2014 [23]. Since the
wave of 2009, in-depth study has been conducted in
the eight longevity areas [24], which included cogni-
tive function, laboratory assessment, the questionnaire
assessment, physical examination and anthropometric
measurement.
Of 3163 potential participants aged 60 years and over,
we excluded 91 people with dementia, Parkinson disease
and stroke based on questionnaire, and 127 people with
unreliable body mass index (BMI) (BMI < 10 or BMI >
60). We also excluded 654 participants with a Mini-
Mental State Examination (MMSE) score of less than or
equal to 10 because cognitive function was too impaired
to be able to complete the cognitive tests or question-
naires, leaving 2,291 eligible participants. There were
1,056 participants who died during the follow-up or loss
of follow-up, and 76 people with incomplete covariate
information, leaving 1,159 individuals with at least two
cognitive tests during the follow-up for the current ana-
lysis. Specifically, 390 participants participated cognitive
test in 2009, 1,116 participants participated cognitive test
in 2012, and 1072 participants participated the test in
2014. Compared with those eligible participants, individ-
uals who died or lost to follow up, had an older age,
higher percentage of women, less years of education,
lower BMI, blood total cholesterol (TC), low density
lipoprotein cholesterol (LDL-C) and MMSE scores at
the baseline (P < 0.05 for all). The study was approved by
the Institutional Review Board of Peking University,
China. Informed consent was obtained from the partici-
pants or their representatives.
Assessment of lipid profile
At the baseline, 12-h overnight fasting plasma TC, LDL-
C, HDL-C, and triglyceride (TG) were measured by an
Automatic Biochemistry Analyzer (Hitachi 7180, Japan),
using commercially available diagnostic kits (Roche
Diagnostic, Mannheim, Germany) in the central clinical
lab at Capital Medical University in Beijing. TC and TG
concentrations were both measured by standard enzym-
atic methods (CHOD-PAP and GPO-PAP; Roche Diag-
nostics). HDL-C was measured by a direct method, and
LDL-C was determined by the Friedewald formula
(LDL-C = TC - HDL-C - TG/2.17 (in mmol/L)). LDL-C
plays a role in forming plaque, a thick, hard deposit that
can clog arteries and make them less flexible, i.e., athero-
sclerosis. Less than 3.37 mmol/L of LDL-C concentra-
tion is considered normal. TG is used to store excess
energy as another type of fate and high levels of TG are
associated with atherosclerosis. The normal range of TG
concentration is less than 1.70 mmol/L. HDL-C helps
remove LDL-C from the arteries, and higher than
1.55 mmol/L of HDL-C concentration is the normal ex-
pected level. As a combination of LDL-C, TG and HDL-
C, high concentrations of TC is also an atherogenic
marker. The desirable concentration of TC is less than
5.18 mmol/L.
Assessment of cognitive function
Global cognitive functions were assessed at 2009, 2012
and 2014, using the validated Chinese version of MMSE,
which was culturally translated into Chinese language
on the basis of the international standard of MMSE
questionnaire [25]. MMSE scores ranged from 0 to 30,
with the indication that higher scores reflect better cog-
nitive function.
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Assessment of potential covariates
Potential covariates included sociodemographic informa-
tion (age, sex, and education levels), behavior and life-
style (smoking status, alcohol intake, and physical
activity), depression symptoms, physical examination
(BMI, and waist circumference), hypertension, and la-
boratory indexes (plasma glucose, C-reactive protein and
uric acid). Among the above data, sociodemographic in-
formation, behavior and lifestyle and depression symp-
toms were collected at baseline via questionnaires,
Weight and height were measured by trained medical
personnel. BMI was calculated as body weight (kg) di-
vided by the square of height (m2). The waist circumfer-
ence was measured to the nearest 0.1 cm at the
midpoint between the bottom of the rib cage and the
top of the iliac crest at the end of exhalation. Systolic
and diastolic blood pressures were measured twice from
the seated position using a mercury sphygmomanom-
eter. The average of the two readings was used for ana-
lysis. Plasma glucose and uric acid were assessed
together with the lipid profile by an Automatic Bio-
chemistry Analyzer (Hitachi 7180, Japan), using com-
mercially available diagnostic kits (Roche Diagnostic,
Mannheim, Germany).
Statistical analyses
To evaluate the relation of blood lipid profile to cogni-
tion we examined mean performance at each assessment
using linear mixed models (which permits examination
of each time point, taking into account lipid profile sta-
tus at baseline and an interaction between lipid profile
status and time). We considered a number of potential
confounders for inclusion in each model: model 1 was
adjusted for sociodemographic information; model 2 was
adjusted for sociodemographic information, behavior
and lifestyle; model 3 was adjusted for all the covariates
stated before. Education was categorized as illiteracy, 1–
6 years or ≥6 years. Smoking status was categorized as
non-smoker and smoker (0, 0.7–20.4, 20.5–44.4, or
44.5–220 pack-year). Alcohol intake was categorized as
non-drinker and drinker (0, 0.4–2.11, 2.12–4.67, or
4.68–67.7 servings/d). BMI was categorized by 17.5,
17.5–23.0, 23.0–27.9, or ≥28.0 kg/m2. Waist circumfer-
ence was categorized by 50–73, 74–80, 81–88, or 89–
155 cm. Plasma glucose was categorized by 0.15–3.93,
3.94–4.68, 4.69–5.41, or 5.42–36.04 mmol/L. C-reactive
protein was categorized by <1, 1–2.9, or ≥3 mg/L. Uric
acid was categorized by <240, 240–360, or ≥360 for
women, and <240, 240–420, or ≥420 μmol/L for men.
Physical activity, depression symptoms and hypertension
were classified as yes or no. The estimate for the effect
of “lipid profile status” reflected the cross-sectional im-
pact of the lipid profile status on cognitive function at
baseline and was presented as the “cross-sectional
effect.” The estimate for the effect of “time” reflected the
annual change in cognitive function and was presented
as “change over time.” The estimate for “interaction” of
the lipid profile status and time reflected the additional
annual impact of the lipid profile status on cognitive
function and was presented as “additional annual effect.”
We examined linear trends across quartiles of a given
lipid using a continuous variable in which participants in
a given category were assigned the median value.
Given the possibility that age (60–79 y, 80–99 y, and
100+ y) and sex at baseline could modify the association
between lipid profile and cognitive decline, interaction
terms for these variables and lipid profile were evaluated,
and subgroup analyses by these variables were further
conducted. All statistical analyses were conducted using
SAS version 9.4 (SAS Institute, Inc, Cary, NC). Formal
hypothesis testing will be 2-sided with a significant
level of 0.05.
Results
Of 1,159 participants, 48.7% were women. The mean age
was 79.4 years (ranged 60–112 y) and the mean educa-
tion years was two years (ranged 0–19 years). Compared
with those with a lower TC concentration, participants
with a higher TC concentration had an older age, a
higher percentage of women and hypertension, a higher
BMI, blood uric acid and LDL-C concentration, and a
larger waist circumference (P < 0.05) (Table 1). No differ-
ences were observed with other covariates.
Higher concentrations of TC and LDL-C were associ-
ated with faster decline in the MMSE score over time
(Table 2). Adjusted mean difference in annual cognitive
decline rate, comparing two extreme quartiles, was -0.28
points (95% confidence interval (CI): -0.54, -0.02; P
trend = 0.005) for TC and -0.42 points (95% CI: -0.69,
-0.16; P trend = 0.006) for LDL-C. The magnitudes were
equivalent to 2.0- and 3.0-year ageing observed in the
current study, respectively. In contrast, we did not ob-
serve significant relations between HDL-C/TG concen-
trations and cognitive decline (P trend > 0.05 for both).
We did not find any significant interaction between
age, sex, and cognitive decline (P for interaction >0.05
for all; Figs. 1 and 2). However, in a subgroup analysis,
the associations between all lipids and cognitive decline
appeared to be more pronounced among individuals
aged 100 years or older (n = 90), relative to others (Fig. 1
& Additional file 1).
Discussion
In this community-based longitudinal study of over
1,100 Chinese older adults living in rural area, we
observed that higher blood concentrations of TC and
LDL-C were associated with faster cognitive decline, in-
dependent of numerous potential co-determinants of
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decline, including diabetes, hypertension, and blood uric
acids concentration.
Consistent with our findings, one 7-year longitudinal
study with 6,855 French participants (mean age = 74 y)
showed that higher TC and LDL-C concentrations in
men were associated with a higher risk of cognitive de-
cline over time [7]. Similar results were observed in an-
other longitudinal study of 1037 US postmenopausal
women with 4 years of follow-up (mean age = 71 y),
reporting that individuals with decrement of TC over
time was associated with lower odds of impairment [8].
In contrast, there have been a few US-based studies
reporting that total serum cholesterol concentrations in
subjects older than 65 years were not associated with
the incidence of dementia during follow-up [10, 11].
Given that participants in those longitudinal studies
were all Caucasians, racial and ethnic differences might
account for the result discrepancies. Further, the
cholesterol-lowering medication (primarily statins) use
was up to 66.5% in high-income countries [22], while
the using rate in China was only 1.7% throughout the
country, much less in the rural areas (0.4%) [21, 22].
Consistently, in another national survey in China based
on 23,129 Chinese adults aged 30-79 years with cardio-
vascular disease, only 1.4% of participants used statins
during 2004–08; the prevalence of statin use was signifi-
cantly lower among those with lower education and
household income, relative to their counterparts [26]. In
this context, we speculate that the different results
observed in our studies and some previous studied
conducted in high-income counties could be partially
explained by statin use. However, there have been no
longitudinal studies, to our knowledge, on the lipid-
cognition relation in general population, stratified by sta-
tin use.
We also found that the lipid-cognition association was
more pronounced in individuals aged 100 years or older,
relative to others. This could be due to the faster cogni-
tive decline rate in this age group, relative to their youn-
ger counterparts. However, significant association
between lipid and cognitive function was not observed
in a previous cross-sectional study conducted in cente-
narians [27]. One possible explanation for this discrep-
ancy may be the current study’s longer follow up period,
which may have better captured cognitive trajectories. It
is also possible that cardiovascular events due to the low
prevalence of statin use could lead to cognitive decline.
However, the interaction between age and cholesterol
concentrations was not significant in the current study,
which was probably due to the small number in centen-
arian group (n = 90). We cannot exclude the possibility
of chance finding.
Some possible biological mechanisms may explain the
observed association between high cholesterol concen-
trations and faster cognitive decline in the current study.
Compared to cholesterol of the periphery with de novo
synthesis and provided by diet half and half, brain chol-
esterol is stable, with the major input solely through de
novo synthesis locally rather than transfer from the per-
iphery. Therefore, the central nervous system contains
its own supple of lipoproteins [12]. Brain cholesterol has
been implicated to play a role in altering the degradation
Table 1 Characteristics by quartile of baseline total cholesterola
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trendb
0.35–3.46 mmol/L 3.47–4.14 mmol/L 4.15–4.84 mmol/L 4.85–8.79 mmol/L
No. 290 287 293 289
Age, y 78.4 (0.64) 79.0 (0.63) 80.4 (0.64) 80.0 (0.64) 0.03
Women, % 39.3 37.3 56.7 61.3 <0.001
Education, y 2.34 (0.18) 2.46 (0.18) 2.29 (0.18) 2.81 (0.19) 0.14
Smoking status, pack-year 8.59 (1.12) 8.87 (1.14) 7.59 (1.11) 10.98 (1.13) 0.25
Alcohol intake, servings/d 0.98 (0.47) 1.99 (0.48) 1.83 (0.47) 1.58 (0.48) 0.45
Physical activity, % 21.1 19.5 20.1 23.7 0.84
Depression symptoms, % 7.0 6.9 5.6 6.9 0.23
Body mass index, kg/m2 21.0 (0.22) 21.6 (0.22) 21.6 (0.22) 22.5 (0.22) <0.001
Waist circumference, cm 80.2 (0.63) 79.6 (0.64) 81.4 (0.63) 83.5 (0.63) <0.001
Hypertension, % 49.7 55.4 61.4 59.2 0.02
LDL-C, mmol/L 1.66 (0.03) 2.11 (0.03) 2.59 (0.03) 3.45 (0.03) <0.001
Glucose, mmol/L 5.10 (0.13) 4.71 (0.13) 4.99 (0.13) 4.88 (0.13) 0.51
Uric acids, μmol/L 272.5 (4.90) 278.2 (4.94) 284.1 (4.87) 299.9 (4.94) <0.001
aValues are mean (standard error) adjusted for age and sex
bAdjusted for age and sex
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of the amyloid precursor protein, which could have im-
pact on the accumulation of amyloid beta peptides, con-
tributing to the pathogenesis of dementia [12]. In
addition, hypercholesterolemia is involved in atherogen-
esis, which could result in macro- and micro- vascular
diseases, deteriorating cognitive function both at sub-
clinical [28, 29] and clinical levels [30].
Strengths of this study include its longitudinal design,
inclusion of centenarians, and incorporation of time-
dependent covariates. However, our study was limited by
lack of a comprehensive neuropsychological battery to
capture all detailed aspects of cognitive function. The
MMSE is a relatively simple screening tool for dementia.
Nevertheless, we measured the MMSE at three time
points, which would allow us to capture the global pat-
tern of cognitive change over time. Residual confound-
ing is of concern because we did not collect information
on ApoE genotype and dietary intake. Another limitation
is high rate of loss to follow-up due to the old age and
low education status of our participants. The diagnoses
of dementia, Parkinson disease and stroke were not con-
firmed by review of medical records.
Fig. 2 Mean difference in annual cognitive change for each mmol/L increment of lipid concentrations, stratified by sex a. Abbreviation: TC = total
cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; TG = triglyceride.P interaction > 0.50 for all,
suggesting that the association between lipids and cognitive decline was not modified by sex. a Adjusted for age, sex, education (illiteracy, 1–6 years,
or ≥6 years), smoking status (non-smoker and smoker (0.7–20.4, 20.5–44.4, or 44.5–220 pack-year)), alcohol intake (non-drinker and drinker (0.4–2.11,
2.12–4.67, or 4.68–67.7 servings/d)), physical activities (yes/no), depression symptoms (yes/no), BMI (<17.5, 17.5–23.0, 23.0–27.9, or ≥28.0 kg/m2), waist
circumference (50–73, 74–80, 81–88, or 89–155 cm), hypertension (yes/no), plasma glucose (0.15–3.93, 3.94–4.68, 4.69–5.41, or 5.42–36.04 mmol/L),
C-reactive protein (<1, 1–2.9, or ≥3 mg/L) and uric acid (women: <240, 240–360, or ≥360; men: <240, 240–420, or ≥420 μmol/L)
Fig. 1 Mean difference in annual cognitive change for each mmol/L increment of lipid concentrations, stratified by age a. Abbreviation: TC = total
cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; TG = triglyceride. P interaction > 0.50 for all,
suggesting that the association between lipids and cognitive decline was not modified by age. aAdjusted for age, sex, education (illiteracy, 1–6 years,
or ≥6 years), smoking status (non-smoker and smoker (0.7–20.4, 20.5–44.4, or 44.5–220 pack-year)), alcohol intake (non-drinker and drinker (0.4–2.11,
2.12–4.67, or 4.68–67.7 servings/d)), physical activities (yes/no), depression symptoms (yes/no), BMI (<17.5, 17.5–23.0, 23.0–27.9, or ≥28.0 kg/m2), waist
circumference (50–73, 74–80, 81–88, or 89–155 cm), hypertension (yes/no), plasma glucose (0.15–3.93, 3.94–4.68, 4.69–5.41, or 5.42–36.04 mmol/L),
C-reactive protein (<1, 1–2.9, or ≥3 mg/L) and uric acid (women: <240, 240–360, or ≥360; men: <240, 240–420, or ≥420 μmol/L)
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Conclusions
In conclusion, higher blood concentrations of TC and
LDL-C in late-life were associated with faster global cog-
nitive decline in this older Chinese rural population. The
associations appeared to be stronger among those aged
100 years or older. Further studies with ApoE data avail-
able, larger sample size, and a comprehensive neuro-
psychological battery to capture specific cognitive effects
are warranted to confirm our findings.
Additional file
Additional file 1: Mean difference in annual cognitive change for each
mmol/L increment of lipid concentrations, stratified by age. (DOCX 13 kb)
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